In particular, lenvatinib had a preferred role on better PFS for those patients in BCLC stage C, with HBV infection, without HCV infection, with EHM, without MVI, with tumor size <6 cm, or with AFP level <200 ng/ml. This evidence concerns the gene AFP and neoplasm.